Tylvalosin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tylvalosin
DrugBank Accession Number
DB11554
Background

Not Available

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 1042.267
Monoisotopic: 1041.587229585
Chemical Formula
C53H87NO19
Synonyms
  • Tylvalosin

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Tylvalosin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Tylvalosin.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Tylvalosin.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Tylvalosin.
AmbroxolThe risk or severity of methemoglobinemia can be increased when Tylvalosin is combined with Ambroxol.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Tylvalosin tartrateAL5667FY0W63428-13-7OLLSDNUHBJHKJS-XKORHJEPSA-N
International/Other Brands
Aivlosin

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / Disaccharides / O-glycosyl compounds / Tricarboxylic acids and derivatives / Fatty acid esters / Oxanes / Alpha-hydrogen aldehydes / Tertiary alcohols / 1,2-aminoalcohols / Trialkylamines
show 11 more
Substituents
1,2-aminoalcohol / Acetal / Alcohol / Aldehyde / Aliphatic heteromonocyclic compound / Alpha-hydrogen aldehyde / Amine / Amino acid or derivatives / Aminoglycoside core / Carbonyl group
show 26 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
9T02S42WQO
CAS number
63409-12-1
InChI Key
KCJJINQANFZSAM-HZDSEHBESA-N
InChI
InChI=1S/C53H87NO19/c1-16-38-36(26-65-52-49(64-15)48(63-14)44(60)31(7)67-52)22-28(4)17-18-37(57)29(5)23-35(19-20-55)46(30(6)39(69-34(10)56)24-41(59)70-38)73-51-45(61)43(54(12)13)47(32(8)68-51)72-42-25-53(11,62)50(33(9)66-42)71-40(58)21-27(2)3/h17-18,20,22,27,29-33,35-36,38-39,42-52,60-62H,16,19,21,23-26H2,1-15H3/b18-17+,28-22+/t29-,30+,31-,32-,33+,35+,36-,38-,39-,42+,43-,44-,45-,46-,47-,48-,49-,50+,51+,52-,53-/m1/s1
IUPAC Name
(2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6R)-6-{[(4R,5S,6S,7R,9R,11E,13E,15R,16R)-4-(acetyloxy)-16-ethyl-15-({[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-5,9,13-trimethyl-2,10-dioxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl 3-methylbutanoate
SMILES
CC[C@H]1OC(=O)C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC

References

General References
  1. Guedes RM, Franca SA, Machado GS, Blumer MA, da Costa Cruz EC Jr: Use of tylvalosin-medicated feed to control porcine proliferative enteropathy. Vet Rec. 2009 Sep 19;165(12):342-5. [Article]
  2. Forrester CA, Bradbury JM, Dare CM, Domangue RJ, Windsor H, Tasker JB, Mockett AP: Mycoplasma gallisepticum in pheasants and the efficacy of tylvalosin to treat the disease. Avian Pathol. 2011 Dec;40(6):581-6. doi: 10.1080/03079457.2011.618822. [Article]
  3. Cerda RO, Petruccelli M, Piscopo M, Origlia J, Landoni M: Impact of the type of catheter on the absorption of tylvalosin (acetylvaleryltylosin) administered orally to broiler chickens. J Vet Pharmacol Ther. 2010 Apr;33(2):202-3. doi: 10.1111/j.1365-2885.2009.01103.x. [Article]
  4. Garces-Narro C, Barragan JI, Soler MD, Mateos M, Lopez-Mendoza MC, Homedes J: Efficacy of low-dose tylvalosin for the control of clostridiosis in broilers and its effect on productive parameters. Poult Sci. 2013 Apr;92(4):975-8. doi: 10.3382/ps.2012-02750. [Article]
  5. Bohm DA, Stachel CS, Gowik P: Validation of a multi-residue method for the determination of several antibiotic groups in honey by LC-MS/MS. Anal Bioanal Chem. 2012 Jul;403(10):2943-53. doi: 10.1007/s00216-012-5868-z. Epub 2012 Feb 26. [Article]
  6. Svartstrom O, Karlsson F, Fellstrom C, Pringle M: Characterization of Treponema spp. isolates from pigs with ear necrosis and shoulder ulcers. Vet Microbiol. 2013 Oct 25;166(3-4):617-23. doi: 10.1016/j.vetmic.2013.07.005. Epub 2013 Jul 17. [Article]
  7. Duinhof TF, Dierikx CM, Koene MG, van Bergen MA, Mevius DJ, Veldman KT, van Beers-Schreurs HM, de Winne RT: [Multiresistant Brachyspira hyodysenteriae in a Dutch sow herd]. Tijdschr Diergeneeskd. 2008 Jul 15-Aug 1;133(14-15):604-8. [Article]
  8. Hidalgo A, Carvajal A, Vester B, Pringle M, Naharro G, Rubio P: Trends towards lower antimicrobial susceptibility and characterization of acquired resistance among clinical isolates of Brachyspira hyodysenteriae in Spain. Antimicrob Agents Chemother. 2011 Jul;55(7):3330-7. doi: 10.1128/AAC.01749-10. Epub 2011 May 9. [Article]
  9. Pringle M, Landen A, Unnerstad HE, Molander B, Bengtsson B: Antimicrobial susceptibility of porcine Brachyspira hyodysenteriae and Brachyspira pilosicoli isolated in Sweden between 1990 and 2010. Acta Vet Scand. 2012 Sep 21;54:54. doi: 10.1186/1751-0147-54-54. [Article]
  10. Tavio MM, Poveda C, Assuncao P, Ramirez AS, Poveda JB: In vitro activity of tylvalosin against Spanish field strains of Mycoplasma hyopneumoniae. Vet Rec. 2014 Nov 29;175(21):539. doi: 10.1136/vr.102458. Epub 2014 Sep 2. [Article]
ChemSpider
4945313
RxNav
1368469
ChEMBL
CHEMBL2103834

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
PowderOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0361 mg/mLALOGPS
logP3.8ALOGPS
logP4.63Chemaxon
logS-4.5ALOGPS
pKa (Strongest Acidic)12.57Chemaxon
pKa (Strongest Basic)8.43Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count17Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area250.81 Å2Chemaxon
Rotatable Bond Count19Chemaxon
Refractivity264.29 m3·mol-1Chemaxon
Polarizability111.37 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fkc-7100000095-78866c62b825fe93b55d
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-9000000018-ea6bcdb50177afe56d9a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9400100344-e59427a09ef5d8844284
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0532-9200000134-bb5faa921ea2e62e1448
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-006w-5911422140-c90dd8df04b3d4c9bcd0
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9102010223-6fb1464e75ff50b69cc9
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at February 26, 2016 17:46 / Updated at April 21, 2021 06:20